Ovarian hyperstimulation syndrome – it's time to reverse the trend
By Geeta Nargund,
BioNews
| 12. 05. 2016
Appeared in BioNews 880
Severe ovarian hyperstimulation syndrome (OHSS) is a serious and potentially fatal condition caused by overstimulation of the ovaries by drugs during IVF treatment. It is preventable with the modern management of IVF cycles, and the incidence of the condition should therefore be falling precipitously to almost zero – as it is in many countries. Indeed, my own clinic has not had a case of severe OHSS for over 15 years. However, in its latest report on adverse incidents in fertility clinics, the Human Fertilisation and Embryology Authority (HFEA) noted a 'slight increase' in the number of severe OHSS incidents reported to it in 2015 (1). In fact, this statement obfuscates the significance of the matter – there has been a 40 percent rise in hospital admissions with severe OHSS in UK fertility clinics in 2015 (2). This is an extraordinary statistic. The HFEA should be putting this alarming statistic on the front page and discussing methods to reverse this trend. Yet the very opposite appears to be the case. It is impossible to extract the number of OHSS...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
By Judd Boaz and Elise Kinsella, ABC News | 03.17.2026
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...